Table 2.
Participant Characteristics
| Study | N | Number of men n (%) |
Ages | Prior fracture n (%) |
DXA n (%) |
Pharmacotherapy or mineral supplementation n (%) |
Osteoporosis diagnosis n (%) |
|---|---|---|---|---|---|---|---|
| Beaton et al.a | 24 | 6 (25) | 47–80 | 24 (100) | 22 (92) | 20 (83) | NRd |
| Edwards et al. | 29 | 0 | ≥ 40 | 29 (100) | 16 (55) | 9 (31) | 26 (90) |
| Emmett et al. | 30 | 0 | ≥ 70 | 8 (27) | 30 (100) | 7 (23) | NR |
| Feldstein et al. | 10 | 0 | ≥ 67 | 10 (100) | 0 | 0 | NR |
| Meadows and Mrkonjic | 19 | 0 | 40–65 | 19 (100) | NR | NR | NR |
| Meadows et al. (2004)b | 24 | 0 | ≥ 40 | 24 (100) | NR | ~12 (~50)e | ~12 (~50) |
| Meadows et al. (2005)b | 22 | 0 | NRf | 22 (100) | NR | NR | NR |
| Rothmann | 31 | 0 | 65–80 | NR | NR | NR | 6 (19) |
| Sale et al. (2010)a | 24 | 6 (25) | 47–80 | 24 (100) | 21 (88) |
9 (38, bisphosphonate) 1 (4, hormone replacement therapy) 16 (67, calcium and vitamin D) 2 (8, calcium) 1 (4, vitamin D) |
~12 (~50) |
| Sale et al. (2014a) | 25 | 3 (12) | ≥ 50 | 25 (100) | 18 (72) | ~4 (~16) | NR |
| Sale et al. (2014b)c | 28 | 2 (7) | 51–89 | 28 (100) | 28 (100) | 19 (68) | 25 (89) |
| Sale et al. (2015)c | 28 | 2 (7) | 51–89 | 28 (100) | 28 (100) | 19 (68) | NR |
| Solimeo et al. | 23 | 23 (100) | ≥ 50 | 13 (57) | NR | 17 (74) | 23 (100) |
a,b,cArticles from the same studies
dNot reported
eOnly estimates reported
fReported as “in midlife”